Evidence map›Paper›PMID 36505757›Full record

Trial reportMediators of inflammation2022

The Effect of Pomegranate Juice and Sumac Consumption in the Treatment of Outpatients with COVID-19.

Fatemeh Forouzanfar, Mohammadreza Ahmadpoor, Mostafa Moshirian Farahi, Ali Hadianfar, Amirhossein Sahebkar, Habibollah Esmaily, Mohsen Nematy, Hassan Rakhshandeh

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Mediators of inflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. The Nutraceutical Properties ofInternational journal of molecular sciences · 2023
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Fatemeh ForouzanfarNeuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0003-0023-6470
Mohammadreza AhmadpoorDepartment of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mostafa Moshirian FarahiPharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.
Ali HadianfarStudent Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
Amirhossein SahebkarApplied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Habibollah EsmailySocial Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohsen NematyDepartment of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hassan RakhshandehPharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0002-2118-1096
Mashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: COVID-19, an epidemic of coronavirus infection, has become a major global threat. The coronavirus mainly targets the human respiratory system, followed by cytokine storm, and altered immune responses associated with disease progression and adverse outcomes. Sumac and pomegranate juice are rich in bioactive compounds, which potentially have antiviral activities. This study is aimed at investigating the effect of a diet based on the use of sumac and pomegranate juice on the treatment of outpatients with COVID-19. Methods: In this study, 182 outpatients with COVID-19 were randomly divided into two groups receiving a diet containing pomegranate juice and sumac along with standard treatment and the control group (group 2) receiving standard treatment. Results: Consumption of a diet containing pomegranate juice and sumac in outpatients with COVID-19, who were receiving standard-of-care treatment, led to a significant decrease in fever, chills, cough, weakness, smell and taste disorders, shortness of breath, diarrhea, nausea and vomiting, and abdominal pain compared with outpatients with COVID-19 who received only standard treatment. Conclusion: Clinical trials of outpatients have limitations such as patients' resilience to post-COVID-19 follow-up. However, the use of pomegranate juice and sumac can be efficacious in reducing COVID-19 symptoms. This trial is registered with IRCT20190406043175N3.

Indexed as

COVID-19RhusCytokine Release SyndromeFruit and Vegetable JuicesHumansOutpatients

Identifiers

PMID36505757
PMCPMC9729036
OpenAlexW4311039305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.